<code id='BB5D762CF1'></code><style id='BB5D762CF1'></style>
    • <acronym id='BB5D762CF1'></acronym>
      <center id='BB5D762CF1'><center id='BB5D762CF1'><tfoot id='BB5D762CF1'></tfoot></center><abbr id='BB5D762CF1'><dir id='BB5D762CF1'><tfoot id='BB5D762CF1'></tfoot><noframes id='BB5D762CF1'>

    • <optgroup id='BB5D762CF1'><strike id='BB5D762CF1'><sup id='BB5D762CF1'></sup></strike><code id='BB5D762CF1'></code></optgroup>
        1. <b id='BB5D762CF1'><label id='BB5D762CF1'><select id='BB5D762CF1'><dt id='BB5D762CF1'><span id='BB5D762CF1'></span></dt></select></label></b><u id='BB5D762CF1'></u>
          <i id='BB5D762CF1'><strike id='BB5D762CF1'><tt id='BB5D762CF1'><pre id='BB5D762CF1'></pre></tt></strike></i>

          comprehensive

          comprehensive

          author:hotspot    Page View:37488
          Two business miniatures talk to each other on coin stacks that are sandwiched by a syringe and a stethoscope — coverage from STAT
          Adobe

          For all the flak they get, the country’s four biggest pharmacy benefit managers reported a surprisingly tame average profit margin in the first three quarters of 2023: 4.5%, less than a third of their drugmaker peers.

          But don’t take their numbers as gospel, experts warned.

          advertisement

          “It’s really easy to move money around inside the books of a vertically integrated organization,” said Karen Van Nuys, a senior fellow at the USC Schaeffer Center for Health Policy and Economics. “If one segment of your vertically integrated organization is not publishing any financial data, it’s a good place to hide stuff.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          ChatGPT in medicine: STAT answers readers' burning questions
          ChatGPT in medicine: STAT answers readers' burning questions

          MikeReddyforSTATArtificialintelligenceisoftendescribedasablackbox:anunknowable,mysteriousforcethatop

          read more
          Biogen joins immunology wave with $1.15 billion acquisition of HI
          Biogen joins immunology wave with $1.15 billion acquisition of HI

          RubyWallauforSTATBiogenisjoiningtheindustry’sfervoroverimmuneandinflammatorydiseasedrugdevelopmentwi

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Liver decline slowed by off

          AdobeWASHINGTON—TherearethreeFDA-approveddrugsfortreatingalcoholusedisorder.Butadifferentmedication,